← Leaderboards
Julien Mamet
Adynxx, Inc.
$3,461,060
Attributed
$6,319,604
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2019–20$5M$3.8M$2.5M$1.3M$0
'19
'20
Funding mix
By agency
NIH$6,319,604 · 2
By mechanism
UG3$5,717,088 · 1
R43$602,516 · 1
Top collaborators
- Donald C Manning2 shared
Others in their field
Other Emerging Leaders on “Pain Reduction”
- Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
- Bryan L McLaughlin · Micro-Leads, Inc.$10,201,646
- Soumitri Sil · Emory University$5,820,476
- Navid Khodaparast · Spark Biomedical Inc$5,635,626
- Brian Hess · Revbio, Inc.$5,591,305
- Joseph A Janicki · Lurie Children'S Hospital Of Chicago$5,541,590
Research focus
Pain ReductionDrug CandidatePain ManagementPostoperative PainDoseOpioid UseOpioid AnalgesicsPainPatient PopulationKnee Replacement ArthroplastyOpioidGrantOperative Surgical ProceduresNon-Opioid AnalgesicClinical TrialsCaringMastectomyInstitutional Review BoardsMeetingsHigh RiskClinically RelevantHydrocodoneFundingEnrollment
Grant awards (3)
The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate$2,858,544
UG3 · FY2020 · DA · contact PI
The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate$2,858,544
UG3 · FY2019 · DA · contact PI
Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain$602,516
R43 · FY2019 · NS · contact PI